Enteric Disease Testing Market Size, Share & Trends Analysis Report By Disease Type (Bacterial, Viral), By Region, And Segment Forecasts, 2020 - 2025

Industry Insights

The global enteric disease testing market size was valued at USD 3.3 billion in 2019 and is expected to reach USD 4.2 billion in 2025 at a CAGR of 2.5% over the forecast period. Vital drivers of this market include technological advancements and supportive government funding in emerging economies. Furthermore, growing global demand for the early diagnostics is expected to enhance the applicability of the market, fueling its growth.

The traditional diagnostic process of enteric diseases was based on the culture method which demanded skilled staff and was a time-consuming procedure. The development of molecular diagnostics and other diagnostic technologies revolutionized this disease testing market over the last decade. The increasing mortality rate due to these conditions and the cost efficiency of the technologically advanced diagnostic systems are expected to drive the demand for early diagnosis of these conditions.

U.S. enteric disease testing market, by disease type, 2014 - 2025 (USD Million)

The initial symptoms witnessed due to enteric disease conditions are abdominal cramps, vomiting, nausea, and anorexia which may lead to severe conditions such as heavy loss of fluids and essential nutrients from the body. Pediatric and geriatric age groups are more prone to these conditions owing to their weak immune system. As per Bill and Melinda Gates Foundation, 500,000 young children under the age of 5 die per annum because of enteric and diarrheal diseases, primarily in developing nations.

The mild initial symptoms are at times ignored and act as a constraint for this market. Enteric diseases are a major cause of morbidity and mortality over the globe with increasing prevalence in developing countries, as these regions have poor drainage and sanitation facilities. It is estimated that developing nations account for more than 85% of these infections in terms of incidence and epidemiology.

Enteric Disease Testing Market Trends

Rising incidence of enteric diseases and the cost-efficiency of technologically advanced diagnostic systems are expected to drive demand for the early diagnosis of enteric disease. For instance, according to the CDC, in the U.S. Salmonella bacteria cause approximately 1.35 million infections, about 420 deaths, and around 26,500 hospitalizations every year. Moreover, a traditional diagnostic procedure such as the culture method required skilled staff and was a tedious & time taking procedure. Development of molecular diagnostics and other diagnostic technologies revolutionized the enteric diseases testing market over the last decade. Thus, increasing demand for early diagnosis of these conditions is expected to drive the enteric disease testing market over the forecast period. 

Increasing incidence of enteric conditions in the developing economies along with a lack of adequate laboratory settings and limited awareness is expected to provide a largely untapped market. As per the Fondation Merieux, enteric diseases are the second leading cause of death among children under 5 years in Asian and African countries. In addition, 90% of deaths caused by diarrhea are due to a lack of access to safe drinking water and basic sanitation facilities. Furthermore, 90% of deaths due to typhoid occur in Asia. Thus, the increasing prevalence of enteric disease and poor sanitation facilities in developing countries provides a largely untapped market. 

Molecular diagnostics are used in various areas of microbiology, which include strain identification and isolation of enteric pathogens. Disease-causing microorganisms are also studied using different molecular diagnostics techniques. The application of molecular diagnostics in microbiology is expected to increase due to the introduction of technologically advanced instruments with improved accuracy levels. Clinical laboratories are adopting molecular diagnostics as a part of laboratory automation. Thus, the rising adoption of molecular diagnostics in the detection of enteric diseases is expected to drive the enteric diseases market over the forecast period. 

Technological advancement is another key factor accelerating market growth. Technological advancements such as gastrointestinal panel tests are used for the identification and qualitative detection of multiple parasitic, bacterial, and viral nucleic acids in individuals with signs & symptoms of gastroenteritis or infectious colitis. The tests are performed on saliva and stool samples to generate rapid results for 15 pathogens in 6 hours. It is also used for testing the inherited food sensitivities/allergies to organisms such as Toxoplasma gondii and Entamoeba histolytica. This test has been approved by the U.S. FDA. Market players undergoing clinical studies to develop the new diagnostic test with high accuracy and high-performance delivery is anticipated to drive the market. For instance, in August 2019, QIAGEN published its multicenter clinical study in the European Journal of Clinical Microbiology & Infectious Diseases (EJCMID) demonstrating the accuracy of QIAstat-Dx syndromic testing for the diagnosis of acute gastroenteritis.

However, the lack of patient awareness in developing countries and the increasing incidence of undiagnosed enteric diseases is expected to impede the growth of this market over the forecast period. In addition, the lack of reimbursement policies in developing countries such as China and India is another factor that may act as a restraint to market growth. High cost of diagnostic facilities limits the entry of new entrants.

During the COVID-19 pandemic, people were very concerned about viral and bacterial infection and thus preferred home-cooked or hygienic food. This resulted in lower infection incidence and declined the number of tests during 2020 and 2021. Also, during the pandemic, the COVID-19 testing was on top priority over any other infectious disease testing, thus the demand for enteric disease testing products declined during the pandemic which hampered the market growth negatively.

Disease Type Insights

Key segments based on disease type are bacterial, viral, and parasitic enteric diseases. Various bacteria that cause these diseases include C. difficile, E. coli, Shigella, Salmonella, and Campylobacter. These form majority of the market with 66.21% of revenue share in 2016 whereas the viral enteric disease testing market held substantial share. Over the next seven years, parasitic disease testing is expected to witness significant growth owing to rising incidences of such infections and the emergence of new parasitic strains. According to the WHO, cholera is estimated to affect 1,72,454 people worldwide per year resulting in increased mortality rate. The WHO further states that in the Asian and American countries, the number of countries reporting cholera cases, have been significantly reduced compared to 2011.

The Child Health Epidemiology Research Group (CHERG), enteric pathogens such as Salmonella spp., Rotavirus, and V. cholera caused more mortality as compared to other enteric pathogen and thus the WHO committee has given the highest priority to the development of new and improved vaccines against these pathogens. Even if some viruses are geographically ubiquitous, such as rotavirus, which infects about 90 percent of the population of the world younger than five years of age, most of the times infections are environmentally determined along with restricted seasonal and geographical patterns that are related to hygiene and degree of sanitation and access to clean drinking water

Regional Insights

Regionally, the market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA. Asia Pacific dominated the market in terms of revenue share with over 29.03% of share in 2021 and is expected to grow at a CAGR of 5.12% over the forecast period. Attractive regions for the market are placed in developing nations such as China and India thereby promoting the fastest growth for Asia Pacific. Asia Pacific is expected to gain 32.35% of the market share by 2030 owing to rising awareness level among people for testing and increasing infections.

Germany holds a considerable share in Europe’s enteric disease testing market, primarily owing to its large geriatric population. According to UN’s population data, one in every 20 people in Germany is aged above 80, which is expected to increase to one in every 6 individuals by 2050. Problems with the increasing geriatric population include a higher risk of enteric diseases due to the onset of senescence & decreased immunity levels. Rapid diagnostic techniques such as point-of-care diagnostic devices are useful for this demographic. Key manufacturers such as Roche and Bio-Rad are strengthening their operations in Germany, which is expected to boost the enteric disease testing market.

Brazil is expected to hold strong opportunities for market growth. Growth in economic & political stability has led to positive economic growth in Brazil. Healthcare reforms, such as the Unified Health System (SUS), provide free healthcare services to individuals at all levels without charging an additional amount. The SUS is a combination of public, private, and supplemental healthcare services.

Supportive government initiatives, such as collaboration between the U.S. and Brazil on biomedical research to accelerate R&D in the diagnosis & treatment of infectious diseases, are also boosting the market. However, access to advanced diagnostics in Brazil is currently limited to urban areas due to the lack of infrastructure in rural settings which could slow down the market growth.

Key Companies & Market Share Insights

The major share of the market is held by companies such as Alere Inc, Bio-Rad Laboratories, Quest Diagnostics, Becton Dickinson and Company, Cepheid, DiaSorin, Meridian BioSciences, and Coris BioConcept. The players are involved in technological advancement and new product development in order to sustain their position in the market and offer cost-efficient solutions. For instance, in November 2014, BioMerieux launched VITEK 2 compact. The reduction in the size of the product increases market scope by the installation of these in laboratories of all sizes. Furthermore, the upgraded technology enhances performance.

Enteric Disease Testing Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. F-or the purpose of this study, Grand View Research has segmented the global enteric disease testing market on the basis of disease type and region:

• Type Outlook (Revenue, USD Million, 2014 - 2025)

  • Bacterial enteric disease

    • C. difficile

    • Campylobacteriosis

    • Cholera

    • E. coli

    • H. pylori

    • Salmonellosis

    • Shigellosis

  • Viral enteric disease

    • Rotavirus

    • Norovirus

  • Parasitic enteric disease

    • Amebiasis

    • Cryptosporidiosis

    • Giardiasis

• Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America

    • The U.S.

    • Canada

  • Europe

    • Germany

    • The U.K.

  • Asia Pacific

    • China

    • Japan

  • Latin America

    • Brazil

    • Mexico

  • Middle East Asia

    • South Africa